|
|
Videx (Didanosine, ddI)
| Brand Name: |
Videx EC |
| Generic Name: |
Didanosine, ddI |
| Adult Single Dose: |
Patients weighing at least 133 lbs
(60 kg): one 400-mg capsule (once a day)
Patients weighing less than 133 lbs (60 kg): one 250-mg capsule (once a day) |
| Food & Liquid Restrictions: |
Take on an empty stomach,
at least 30 minutes before or two hours after eating or drinking, except
water. Do not take Videx EC with food. |
| Drug Class: |
NRTI |
The Basics
- An Overview of Videx (Didanosine, ddI) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Didanosine (Videx, ddI) (October 1, 2009)
To read PDF, click here
From AIDS InfoNet
- Patient Information About Videx (Didanosine, ddI) (PDF) (June 2009)
From Bristol-Myers Squibb Company
- Videx EC (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Videx EC (Didanosine, ddI EC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- ddI (Videx, didanosine) (August 15, 2006)
From AIDS Treatment Data Network
- Videx (Didanosine) (May 2005)
[Archived Article]
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Didanosine (August 2004)
[Archived Article]
From Project Inform
- New ddI Warning (October 2000)
[Archived Article]
In What's New, from Project Inform
- Twice-Daily ddI Recommended (Autumn 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Updates: Pancreatitis Warning for Videx (Spring 2000)
[Archived Article]
In STEP Perspective, from Seattle Treatment Education Project
News
- Important Changes to Videx (Didanosine) Labeling (June 19, 2009)
From U.S. Food and Drug Administration
- Videx EC Labeling Changes With Pediatric Dosing Information Added (September 30, 2008)
From U.S. Food and Drug Administration
- FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules (December 3, 2004)
[Archived Article]
From AIDSinfo
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
[Archived Article]
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Thailand: Patients, Advocates Sue to Invalidate Videx EC Patent (October 10, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- New Safety Information for Videx (Didanosine, ddI) Used With Ribavirin (September 25, 2002)
[Archived Article]
From U.S. Food and Drug Administration
- ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
[Archived Article]
From Bristol-Myers Squibb Company
- Drug Economy (July/August 2001)
[Archived Article]
Antiretroviral renegade fights fashion with didanosine + Hydroxyurea duo, betting his future on genetic barriers.
In TAGline, from Treatment Action Group
- New Formulation of ddI Approved (March 2001)
[Archived Article]
To read PDF, click here
In Project Inform Perspective, from Project Inform
- FDA Issues Warning About d4T and ddI During Pregnancy (January 22, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- FDA Approves Videx EC and Trizivir (November 27, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Enteric-coated ddI Approved: FDA Letter (November 3, 2000)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Videx (Didanosine, ddI) Less Effective at Once-a-Day Dosing? (September 7, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Treatment Briefs: ddI: Once Daily & New Formulation (Winter 1999/2000)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA OKs New Videx Formulation (December 1999)
[Archived Article]
In Positive Living, from AIDS Project Los Angeles
- Recent News About ddI (September 1999)
[Archived Article]
In Project Inform Perspective, from Project Inform
- AZT, ddI, and ddC Combinations at FDA Advisory Hearing (April 5, 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- d4T Plus ddI Antiviral Results (February 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Research
- Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
- Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here
From D:A:D Steering Committee
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
- ddI + Tenofovir Combination Linked to Higher Pancreatitis Risk (October 2004)
[Archived Article]
Quick recap of a report in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
- Further Case Report of Lactic Acidosis Linked to Tenofovir/ddI (September 29, 2003)
[Archived Article]
From aidsmap.com
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Adding ddI Achieves Fall in Viral Load in HAART Patients With Resistance (September 14, 2003)
[Archived Article]
From aidsmap.com
- HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
[Archived Article]
From aidsmap.com
- Didanosine and Tenofovir DF Drug-Drug Interaction: Assessment of Didanosine Dose Reduction (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Questions About an Old Combination -- ddI + d4T (January 2003)
[Archived Article]
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Viread-Videx EC Drug Interactions -- What's a Person to Do? (Fall 2002)
[Archived Article]
To read PDF, click here
In STEP Perspective, from Seattle Treatment Education Project
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Hydroxychloroquine, Hydroxycarbamide, and Didanosine as Economic Treatment for HIV-1 (May 23, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Pancreatitis: An Emerging Complication of HCV Treatment in HIV Co-Infected Patients Treated With Didanosine/Stavudine Containing Regimens (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Effect of Food on Oral Bioavailability of Didanosine From Delayed Release Capsules Containing Enteric Coated Beads (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- ddI Warning (March 2001)
[Archived Article]
In What's New, from Project Inform
- Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Treatment-Naive HIV-Infected Adults: 64-Week Follow-Up of the ANRS 091 Trial (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Viral Resistance Results From the International, Multicenter, Randomized, Placebo-Controlled, 48-Week Study of Hydroxyurea or Placebo Combined With Efavirenz, Didanosine and Stavudine in Treatment-Naive and -Experienced Patients (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Control of Viremia After Treatment Interruption (January 31, 2000)
[Archived Article]
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz (EFV) in Combination With Stavudine (d4T) and Didanosine (ddI) or Lamivudine (3TC) Is Well-Tolerated and Efficacious in the Majority of Patients Treated (October 25, 1999)
[Archived Article]
In The 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Improved Tolerability and Adherence With Reduced Mass Didanosine Tablets in HIV-1 Infected Adults Receiving Highly Active Antiretroviral Therapy (October 1999)
[Archived Article]
In The 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Efficacy of Efavirenz in Combination With Stavudine (d4T) and Didanosine (ddI) in Antiretroviral Therapy-Naïve HIV-Infected Patients (Study 044) (September 28, 1999)
[Archived Article]
In The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Journal Watch: Once Daily ddI as Effective as Twice Daily (July/August 1999)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm3 (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- An Open Label Pilot Study for the Efficacy and Tolerability of Once Daily DDI Versus Twice Daily DDI (September 1997)
[Archived Article]
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Safety and Efficacy of Once-Daily Dose of Didanosine (DDI) (September 1997)
[Archived Article]
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- ddI + d4T Combination Therapy Proves Effective (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Hydroxyurea and ddI: French Study Published (September 1, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
E-Mail
Glossary
Share